1
|
Cai L, Xiong PF, Li T, Li C, Wu ZX, Hong YL, Wang JT, Zhang MY, Yang XQ, Xu QQ, Shi H, Luo QC, Li R, Liu MM. Discovery of novel diaryl substituted isoquinolin-1(2H)-one derivatives as hypoxia-inducible factor-1 signaling inhibitors for the treatment of rheumatoid arthritis. Eur J Med Chem 2024; 271:116417. [PMID: 38688063 DOI: 10.1016/j.ejmech.2024.116417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 04/10/2024] [Accepted: 04/11/2024] [Indexed: 05/02/2024]
Abstract
Since synovial hypoxic microenvironment significantly promotes the pathological progress of rheumatoid arthritis (RA), hypoxia-inducible factor 1 (HIF-1) has been emerged as a promising target for the development of novel therapeutic agents for RA treatment. In this study, we designed and synthesized a series of diaryl substituted isoquinolin-1(2H)-one derivatives as HIF-1 signaling inhibitors using scaffold-hopping strategy. By modifying the substituents on N-atom and 6-position of isoquinolin-1-one, we discovered compound 17q with the most potent activities against HIF-1 (IC50 = 0.55 μM) in a hypoxia-reactive element (HRE) luciferase reporter assay. Further pharmacological studies revealed that 17q concentration-dependently blocked hypoxia-induced HIF-1α protein accumulation, reduced inflammation response, inhibited cellular invasiveness and promoted VHL-dependent HIF-1α degradation in human RA synovial cell line. Moreover, 17q improved the pathological injury of ankle joints, decreased angiogenesis and attenuated inflammation response in the adjuvant-induced arthritis (AIA) rat model, indicating the promising therapeutic potential of compound 17q as an effective HIF-1 inhibitor for RA therapy.
Collapse
Affiliation(s)
- Li Cai
- School of Basic Medicine, Anhui Medical University, Hefei, 230032, Anhui Province, PR China; Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui Province, PR China
| | - Peng-Fei Xiong
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Tao Li
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Chong Li
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Zheng-Xing Wu
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Ya-Ling Hong
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Jin-Ting Wang
- The First Clinical Medical College, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Meng-Yue Zhang
- The Second Clinical Medical College, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Xi-Qin Yang
- The Second Clinical Medical College, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Qian-Qian Xu
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Huan Shi
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China
| | - Qi-Chao Luo
- School of Basic Medicine, Anhui Medical University, Hefei, 230032, Anhui Province, PR China.
| | - Rong Li
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China; Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, 230026, Anhui Province, PR China.
| | - Ming-Ming Liu
- Anhui Province Key Laboratory of Inflammation and Immune Diseases, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China.
| |
Collapse
|
2
|
Vijayakumar A, Manod M, Krishna RB, Mathew A, Mohan C. Diversely functionalized isoquinolines and their core-embedded heterocyclic frameworks: a privileged scaffold for medicinal chemistry. RSC Med Chem 2023; 14:2509-2534. [PMID: 38107174 PMCID: PMC10718595 DOI: 10.1039/d3md00248a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Accepted: 08/23/2023] [Indexed: 12/19/2023] Open
Abstract
Isoquinoline-enrooted organic small-molecules represent a challenging molecular target in the organic synthesis arsenal attributed to their structural diversity and therapeutic importance. Into the bargain, isoquinolines are significant structural frameworks in modern medicinal chemistry and drug development. Consequently, synthetic organic and medicinal chemists have been intensely interested in efficient synthetic tactics for the sustainable construction of isoquinoline frameworks and their derivatives in enantiopure or racemic forms. This review accentuates an overview of the literature on the modern synthetic approaches exploited in synthesising isoquinolines and their core embedded heterocyclic skeletons from 2021 to 2022. In detail, the methodologies and inspected pharmacological studies for the array of diversely functionalized isoquinolines or their core-embedded heterocyclic/carbocyclic structures involving the introduction of substituents at C-1, C-3, and C-4 carbon and N-2 atom, bond constructions at the C1-N2 atom and C3-N2 atom, and structural scaffolding within isoquinoline compounds have been reviewed. This intensive study highlights the need for and relevance of relatively unexplored bioisosterism employing isoquinoline-based small-molecules in drug design.
Collapse
Affiliation(s)
- Archana Vijayakumar
- School of Chemical Sciences, Mahatma Gandhi University Kottayam 686560 India
| | - M Manod
- School of Chemical Sciences, Mahatma Gandhi University Kottayam 686560 India
| | - R Bharath Krishna
- Institute for Integrated Programmes and Research in Basic Sciences, Mahatma Gandhi University Kottayam 686560 India
| | - Abra Mathew
- School of Chemical Sciences, Mahatma Gandhi University Kottayam 686560 India
- Department of Chemistry, Indian Institute of Technology Palakkad Kerala 678577 India
| | - Chithra Mohan
- School of Chemical Sciences, Mahatma Gandhi University Kottayam 686560 India
| |
Collapse
|
3
|
Ghag R, Kaushal M, Nwanne G, Knoten A, Kiryluk K, Rosenberg A, Menez S, Bagnasco SM, Sperati CJ, Atta MG, Gaut JP, Williams JC, El-Achkar TM, Arend LJ, Parikh CR, Jain S. Single Nucleus RNA Sequencing of Remnant Kidney Biopsies and Urine Cell RNA Sequencing Reveal Cell Specific Markers of Covid-19 Acute Kidney Injury. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.11.10.566497. [PMID: 37986991 PMCID: PMC10659401 DOI: 10.1101/2023.11.10.566497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2023]
Abstract
Acute kidney injury (AKI) in COVID-19 patients is associated with high mortality and morbidity. Critically ill COVID-19 patients are at twice the risk of in-hospital mortality compared to non-COVID AKI patients. We know little about the cell-specific mechanism in the kidney that contributes to worse clinical outcomes in these patients. New generation single cell technologies have the potential to provide insights into physiological states and molecular mechanisms in COVID-AKI. One of the key limitations is that these patients are severely ill posing significant risks in procuring additional biopsy tissue. We recently generated single nucleus RNA-sequencing data using COVID-AKI patient biopsy tissue as part of the human kidney atlas. Here we describe this approach in detail and report deeper comparative analysis of snRNAseq of 4 COVID-AKI, 4 reference, and 6 non-COVID-AKI biopsies. We also generated and analyzed urine transcriptomics data to find overlapping COVID-AKI-enriched genes and their corresponding cell types in the kidney from snRNA-seq data. We identified all major and minor cell types and states by using by using less than a few cubic millimeters of leftover tissue after pathological workup in our approach. Differential expression analysis of COVID-AKI biopsies showed pathways enriched in viral response, WNT signaling, kidney development, and cytokines in several nephron epithelial cells. COVID-AKI profiles showed a much higher proportion of altered TAL cells than non-COVID AKI and the reference samples. In addition to kidney injury and fibrosis markers indicating robust remodeling we found that, 17 genes overlap between urine cell COVID-AKI transcriptome and the snRNA-seq data from COVID-AKI biopsies. A key feature was that several of the distal nephron and collecting system cell types express these markers. Some of these markers have been previously observed in COVID-19 studies suggesting a common mechanism of injury and potentially the kidney as one of the sources of soluble factors with a potential role in disease progression. Translational Statement The manuscript describes innovation, application and discovery that impact clinical care in kidney disease. First, the approach to maximize use of remnant frozen clinical biopsies to inform on clinically relevant molecular features can augment existing pathological workflow for any frozen tissue without much change in the protocol. Second, this approach is transformational in medical crises such as pandemics where mechanistic insights are needed to evaluate organ injury, targets for drug therapy and diagnostic and prognostic markers. Third, the cell type specific and soluble markers identified and validated can be used for diagnoses or prognoses in AKI due to different etiologies and in multiorgan injury.
Collapse
|
4
|
Du B, Luo M, Ren C, Zhang J. PDE4 inhibitors for disease therapy: advances and future perspective. Future Med Chem 2023; 15:1185-1207. [PMID: 37470147 DOI: 10.4155/fmc-2023-0101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/21/2023] Open
Abstract
The PDE4 enzyme family is specifically responsible for hydrolyzing cAMP and plays a vital role in regulating the balance of second messengers. As a crucial regulator in signal transduction, PDE4 has displayed promising pharmacological targets in a variety of diseases, for which its inhibitors have been used as a therapeutic strategy. This review provides a comprehensive summary of the development of PDE4 inhibitors in the past few years, along with the structure, clinical and research progress of multiple inhibitors of PDE4, focusing on the research and development strategies of PDE4 inhibitors. We hope our analysis will provide a significant reference for the future development of new PDE4 inhibitors.
Collapse
Affiliation(s)
- Baochan Du
- Department of Neurology, Joint Research Institution of Altitude Health, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Min Luo
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Changyu Ren
- Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, China
| | - Jifa Zhang
- Department of Neurology, Joint Research Institution of Altitude Health, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| |
Collapse
|
6
|
Sangepu VR, Sharma D, Venkateshwarlu R, Bhoomireddy RD, Jain KK, Dandela R, Pal M. Ultrasound Assisted α‐Arylation of Ketones: A Rapid Access to Isoquinolinone Derivatives. ChemistrySelect 2022. [DOI: 10.1002/slct.202202710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Venkateswara Rao Sangepu
- Process Research and Development Dr. Reddy's Laboratories Limited CTO-Unit 5 Peddadevulapally Nalgonda 508207 India
- Department of Chemistry College of Engineering Jawaharlal Nehru Technological University Hyderabad Hyderabad, 500 085 Telangana India
| | - Deepika Sharma
- Department of Industrial and Engineering Chemistry Institute of Chemical Technology, Indianoil Odisha Campus, Samantpuri Bhubaneswar 751013 India
| | - Rapolu Venkateshwarlu
- Process Research and Development Dr. Reddy's Laboratories Limited IDA Bollaram Hyderabad Telangana 502325 India
| | - Rama Devi Bhoomireddy
- Department of Chemistry College of Engineering Jawaharlal Nehru Technological University Hyderabad Hyderabad, 500 085 Telangana India
| | - Kirti Kumar Jain
- Process Research and Development Dr. Reddy's Laboratories Limited IDA Bollaram Hyderabad Telangana 502325 India
| | - Rambabu Dandela
- Department of Industrial and Engineering Chemistry Institute of Chemical Technology, Indianoil Odisha Campus, Samantpuri Bhubaneswar 751013 India
| | - Manojit Pal
- Dr. Reddy's Institute of Life Sciences University of Hyderabad Campus Hyderabad 500046 India
| |
Collapse
|